Table 4.

Postoperative outcomes

	Ustekinumab cohort (n=20)	Anti-TNF cohort (n=40)	P value
Postoperative complications:
Wound infection ≤ 30 days	1 (5%)	2 (5%)	1.00
Wound infection > 30 days	0	0	-
Anastomotic leakage ≤ 30 days	0	3 (7.5%)	0.54
Anastomotic leakage > 30 days	0	0	-
Abscess ≤ 30 days	0	4 (10%)	0.29
Abscess > 30 days	0	2 (5%)	0.54
Nonsurgical site infection ≤ 30 days	0	3 (7.5%)	0.54
Nonsurgical site infection > 30 days	0	0	-
Postoperative ileus /bowel obstruction	3 (15%)	4 (10%)	0.67
Delayed wound healing	0	5 (12.5%)	0.16
Need for reoperation/readmission	2 (10%)	6 (15%)	0.59
Median preoperative hospital stay (days, IQR)	0 (0–4)	0 (0–2)	0.59
Median total hospital stay (days, IQR)	7 (5–14)	7 (4–9)	0.45
Mortality at 6 months	0	0	-